CD8A and neoplasm: The observation that CD8+ T-cells influenced the efficacy of the MRTX849/lapatinib treatment without any evidence of tumor elimination motivated us to explore the involvement of programmed death ligand 1 (PD-L1) as a key negative regulator of CD8+ T-cell activity that facilitates disease progression to such combination therapy.